

TEVA PHARMACEUTICAL INDUSTRIES LTD
Form 6-K
May 12, 2004

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Private Issuer

**Pursuant to Rule 13a-16 or 15d-16
under the Securities Exchange Act of 1934**

For the month of May 2004

Commission File Number 0-16174

Teva Pharmaceutical Industries Limited

(Translation of registrant's name into English)

5 Basel Street, P.O. Box 3190

Petach Tikva 49131 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F

Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also hereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes

No

If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g(3)-2(b): 82-_____

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

(An Israeli Corporation)

INDEX

	<u>Page</u>
Condensed Consolidated Statements of Income (Loss)	1
Condensed Consolidated Balance Sheets	2
Condensed Consolidated Statements of Cash Flows	3
Notes to Condensed Consolidated Financial Statements	4
Operating and Financial Review and Prospects	9
Quantitative and Qualitative Disclosure About Market Risk	18
Legal Proceedings	18

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

CONDENSED CONSOLIDATED STATEMENTS OF INCOME (LOSS)

(U.S. dollars in millions, except earnings (loss) per ADR)

(Unaudited)

	Three months ended March 31, 2004	2003
Net sales	\$ 1,052.4	\$ 757.4
Cost of sales	572.0	409.0
Gross profit	480.4	348.4
Research and development expenses:		
Total expenses	72.0	49.7
Less - participations and grants	3.9	3.3
	68.1	46.4
Selling, general and administrative expenses	158.1	122.7
	254.2	179.3
Acquisition of research and development in process	596.6	-
Impairment of product rights	30.0	-
Operating income (loss)	(372.4)	179.3
Financial expenses - net	1.3	4.0
Income (loss) before income taxes	(373.7)	175.3
Income taxes	54.0	37.7
	(427.7)	137.6
Share in profits of associated companies - net	0.5	0.1
Minority interests in profits of subsidiaries - net	0.8	-
Net income (loss)	\$ (428.0)	\$ 137.7
Earnings (loss) per ADR:		
Basic	\$ (1.44)	\$ 0.52
Diluted	\$ (1.44)	\$ 0.50
Weighted average number of ADRs (in millions):		
Basic	297.9	265.1
Diluted	297.9	282.8

The accompanying notes are an integral part of the condensed financial statements.

1

TEVA PHARMACEUTICAL INDUSTRIES LIMITED

CONDENSED CONSOLIDATED BALANCE SHEETS

(U.S. dollars in millions)

	March 31, 2004 Unaudited	December 31, 2003 Audited
ASSETS		
Current assets:		
Cash and cash equivalents	\$ 710.0	\$ 1,057.3
Short-term investments	211.9	322.1
Accounts receivable:		
Trade	1,220.0	1,031.8
Other	329.2	300.6
Inventories	1,264.7	1,004.6
Total current assets	3,735.8	3,716.4
Investments and other assets	561.6	445.1
Property, plant and equipment, net	1,077.9	827.4
Intangible assets and debt issuance costs, net	756.8	279.5
Goodwill	2,429.3	647.5
Total assets	\$ 8,561.4	\$ 5,915.9
LIABILITIES AND SHAREHOLDERS' EQUITY		
Current liabilities:		
Short-term credit	\$ 356.3	\$ 291.7
Accounts payable and accruals	1,344.3	1,050.7
Convertible Senior Debentures	352.0	352.5
Total current liabilities	2,052.6	1,694.9
Long-term liabilities:		
Deferred income taxes	228.6	34.6
Employee related obligations	78.3	74.9
Loans and other liabilities	360.9	365.5
Convertible Senior Debentures	1,538.6	449.9

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Total long-term liabilities	2,206.4	924.9			
Total liabilities	4,259.0	2,619.8			
Minority interests	7.6	6.7			
Shareholders' equity:					
Ordinary shares of NIS 0.10 par value; March 31, 2004 and December 31, 2003: authorized - 999.6 million; issued and outstanding - 301.9 million and 277.7 million, respectively	35.0	34.3			
Additional paid-in capital	2,599.2	1,159.3			
Deferred compensation	*	*			
Retained earnings	1,502.5	1,960.3			
Accumulated other comprehensive income	205.7	184.0			
Cost of company shares held by subsidiaries - March 31, 2004	1,253,148				
			25,000(b)		
Obligations under capital leases	294,000	250,000(h)	120,000(h)		664,000
Intangible lease liabilities, less accumulated amortization	110,983				110,983
Accounts payable, accrued expenses and accrued capital expenditures	66,320				66,320
Due to affiliates	2,979				2,979
Dividends payable	10,025				10,025
Deferred income	19,594				19,594
Total liabilities	1,478,117	529,832	212,157	(93,057)	2,127,049
Minority Interest	2,333		5,347(i)		7,680
Redeemable Common Stock	647,113				647,113
Stockholders Equity:					
Common stock, \$0.01 par value; 900,000,000 shares authorized; and 408,867,013 shares issued and outstanding as of June 30, 2008	4,089		63 (d)		4,152
Additional paid in capital	3,646,561		56,067 (d)		3,702,628
Cumulative distributions in excess of earnings	(533,101)				(533,101)
Redeemable common stock	(647,113)				(647,113)
Other comprehensive loss	(3,522)				(3,522)
Total stockholders equity	2,466,914		56,130		2,523,044
Total liabilities, minority interest, redeemable common stock and stockholders equity	\$ 4,594,477	\$ 529,832	\$ 217,504	\$ (36,927)	\$ 5,304,886

Table of Contents

- (a) Historical financial information is derived from Wells REIT II's quarterly report filed on Form 10-Q for the quarter ended June 30, 2008.
- (b) Reflects the purchase price of the assets and liabilities obtained by Wells REIT II in connection with the respective acquisition, net of any purchase price adjustments.
- (c) Reflects deferred project costs applied to land and building at approximately 2.312% of the cash paid for purchase upon acquisition and subsequent pay-down of acquisition-related borrowings.
- (d) Reflects capital raised through issuance of additional common stock subsequent to June 30, 2008 through July 31, 2008, the acquisition date of the Three Glenlake Building, net of organizational and offering costs, commissions and dealer-manager fees.
- (e) Reflects deferred project costs capitalized as a result of additional capital raised as described in note (d) above.
- (f) Reflects partial pay down of acquisition-related borrowings using cash on-hand at June 30, 2008 and additional capital raised as described in note (d) above.
- (g) Reflects investment in development authority bond for which 100% of the principal balance related to the Lindbergh Center Buildings becomes receivable in 2012 and 100% of the principal balance related to the Three Glenlake Building becomes receivable in 2017.
- (h) Reflects bond note secured by the deed of trust to the respective property for which 100% of the principal balance related to the Lindbergh Center Buildings becomes payable in 2012 and 100% of the principal balance related to the Three Glenlake Building becomes payable in 2017.
- (i) Reflects the joint venture partner's initial interest in the Three Glenlake Buildings.
The accompanying notes are an integral part of this statement

Table of Contents**WELLS REAL ESTATE INVESTMENT TRUST II, INC.****PRO FORMA STATEMENT OF OPERATIONS****FOR THE YEAR ENDED DECEMBER 31, 2007**

(in thousands, except for per share amounts)

(unaudited)

	Wells Real Estate Investment Trust II, Inc. Historical (a)	2007 Acquisitions	Q1 and Q2 2008 Acquisitions	Lindbergh Center	Pro Forma Total
Revenues:					
Rental income	\$ 322,506	\$ 39,567(b)	\$ 26,710(b)	21,087(b)	\$ 409,870
Tenant reimbursements	83,861	4,121(c)	4,992(c)	2,993(c)	95,967
Hotel income	24,000				24,000
Other rental income	2,783				2,783
	433,150	43,688	31,702	24,080	532,620
Expenses:					
Property operating costs	137,425	13,566(d)	7,345(d)	2,993(d)	161,329
Hotel operating costs	18,004				18,004
Asset and property management fees:					
Related party	28,078	4,935(e)	1,990(e)	1,726(e)	36,729
Other	4,838				4,838
Depreciation	61,289	6,350(f)	5,380(f)	5,438(f)	78,457
Amortization	115,540	10,728(g)	6,897(g)	5,310(g)	138,475
General and administrative	18,580				18,580
	383,754	35,579	21,612	15,467	456,412
Real estate operating income	49,396	8,109	10,090	8,613	76,208
Other income (expense):					
Interest expense	(49,950)	(5,440)(h)	(14,429)(l)	(15,059)(i) (14,800)(l)	(99,678)
Loss on interest rate swaps	(12,173)				(12,173)
Loss on foreign currency exchange contract	(470)				(470)
Interest and other income	9,019		14,429(k)	14,800(k)	38,248
	(53,574)	(5,440)		(15,059)	(74,073)
Income (loss) before minority interest and income tax benefit	(4,178)	2,669	10,090	(6,446)	2,135
Minority interest in earnings of consolidated entities	(30)				(30)
Income (loss) before income tax benefit	(4,208)	2,669	10,090	(6,446)	2,105
Income tax benefit	(460)				(460)
Net income (loss)	\$ (4,668)	\$ 2,669	10,090	(6,446)	\$ 1,645

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Net income (loss) per share	basis and diluted	\$ (0.01)	\$ 0.00
Weighted-average shares outstanding	basic and diluted	328,615	431,404(j)

F-14

Table of Contents

- (a) Historical financial information derived from Wells REIT II's annual report filed on Form 10-K for the year ended December 31, 2007.
- (b) Rental income consists primarily of base rent, parking income and amortization of above-market lease assets and below-market lease liabilities. Base rent is recognized on a straight-line basis beginning on the pro forma acquisition date of January 1, 2007.
- (c) Consists of operating cost reimbursements.
- (d) Consists of property operating expenses.
- (e) Asset management fees calculated as 0.75% of the cost of the acquisitions on an annual basis limited to 1% of the net asset value of such acquisitions after deducting debt used to finance acquisitions.
- (f) Depreciation expense on portion of purchase price allocated to Building is recognized using the straight-line method and a 40-year life.
- (g) Amortization of deferred leasing costs and lease intangibles is recognized using the straight-line method over the lives of the respective leases.
- (h) Represents interest expense on the \$130.3 million mortgage loan originated in connection with the acquisition of 222 East 41st Street that bears interest at 6.675% and matures on August 16, 2017.
- (i) Represents additional interest expense that would have been incurred if the balance of the Wachovia \$450.0 million line of credit for the period was equal to the pro forma line of credit balance per the Pro Forma Balance Sheet as of June 30, 2008. The line of credit bore interest at approximately 6.25% for the year ended December 31, 2007.
- (j) Reflects issuance of additional shares of common stock subsequent to December 31, 2007 through July 31, 2008.
- (k) Represents interest income related to development authority revenue bonds issued by the respective development authorities and assumed upon acquisition of the Lenox Park Buildings and the Lindbergh Center Buildings. The development authority bonds related to the Lenox Park Buildings and the Lindbergh Center Buildings earn interest at approximately 6.68% and 5.92%, respectively.
- (l) Represents interest expense related to the bond notes assumed at the acquisition of the Lenox Park Buildings and the Lindbergh Center Buildings.

The accompanying notes are an integral part of this statement

Table of Contents**WELLS REAL ESTATE INVESTMENT TRUST II, INC.****PRO FORMA STATEMENT OF OPERATIONS****FOR THE SIX MONTHS ENDED JUNE 30, 2008****(in thousands, except for per share amounts)****(unaudited)**

	Wells Real Estate Investment Trust II, Inc. Historical (a)	Q1 and Q2 2008 Acquisitions	Pro Forma Adjustments Q3 2008 Acquisition		Pro Forma Total
			Lindbergh Center	Three Glenlake	
Revenues:					
Rental income	\$ 188,320	\$ 7,924 (b)	\$ 10,544 (b)	\$ 1,614 (b)	\$ 208,402
Tenant reimbursements	49,788	1,454 (c)	1,414 (c)	612 (c)	53,268
Hotel income	11,196				11,196
Other rental income	768				768
	250,072	9,378	11,958	2,226	273,634
Expenses:					
Property operating costs	79,357	1,453 (d)	1,414 (d)	612 (d)	82,836
Hotel operating costs	8,447				8,447
Asset and property management fees:					
Related party	16,991	947 (e)	822 (e)		18,760
Other	2,057				2,057
Depreciation	36,343	1,644 (f)	2,720 (f)	654 (f)	41,361
Amortization	59,226	3,449 (g)	2,655 (g)	383 (g)	65,713
General and administrative	12,245				12,245
	214,666	7,493	7,611	1,649	231,419
Real estate operating income	35,406	1,885	4,347	577	42,215
Other income (expense):					
Interest expense	(31,485)	(5,074)(k)	(4,734)(h) (7,400)(k)	(571)(h) (373)(l) (1,800)(k)	(51,437)
Gain on early extinguishment of debt	2,971				2,971
Loss on interest rate swaps	(639)				(639)
Loss on foreign currency exchange contract	(1,305)				(1,305)
Interest and other income	6,001	5,074 (k)	7,400 (j)	1,800 (j)	20,275
	(24,457)		(4,734)	(944)	(30,135)
Income (loss) before minority interest and income tax benefit	10,949	1,885	(387)	(367)	12,080
Minority interest in earnings of consolidated entities	24				24
Income (loss) before income tax benefit	10,973	1,885	(387)	(367)	12,104
Income tax benefit	(489)				(489)
Net income (loss)	\$ 10,484	\$ 1,885	\$ (387)	\$ (367)	\$ 11,615

Edgar Filing: TEVA PHARMACEUTICAL INDUSTRIES LTD - Form 6-K

Net income (loss) per share	basis and diluted	\$	0.03	\$	0.03
Weighted-average shares outstanding	basic and diluted		388,108		431,404(i)

F-16

Table of Contents

- (a) Historical financial information derived from Wells REIT II's quarterly report filed on Form 10-Q for the six months ended June 30, 2008.
- (b) Rental income consists primarily of base rent, parking income and amortization of above-market lease assets and below-market lease liabilities. Base rent is recognized on a straight-line basis beginning on the pro forma acquisition date of January 1, 2007.
- (c) Consists of operating cost reimbursements.
- (d) Consists of property operating expenses.
- (e) Asset management fees calculated as 0.75% of the cost of the acquisitions on an annual basis limited to 1% of the net asset value of such acquisitions after deducting debt used to finance acquisitions.
- (f) Depreciation expense on portion of purchase price allocated to Building is recognized using the straight-line method and a 40-year life.
- (g) Amortization of deferred leasing costs and lease intangibles is recognized using the straight-line method over the lives of the respective leases.
- (h) Represents additional interest expense that would have been incurred if the balance of the Wachovia \$450.0 million line of credit for the period was equal to the pro forma line of credit balance per the Pro Forma Balance Sheet as of June 30, 2008. The line of credit bore interest at approximately 3.94% for the six months ended June 30, 2008.
- (i) Reflects issuance of additional shares of common stock subsequent to June 30, 2008 through July 31, 2008.
- (j) Represents interest income earned on development authority revenue bonds issued by the respective development authorities and assumed upon acquisition of the Lenox Park Buildings, the Lindbergh Center Buildings and the Three Glenlake Building. The development authority bonds related to the Lenox Park Buildings, the Lindbergh Center Buildings and the Three Glenlake Building earn interest at approximately 6.68%, 5.92% and 6.00%, respectively.
- (k) Represents interest expense related to the bond notes assumed upon acquisition of the Lenox Park Buildings, the Lindbergh Center Buildings and the Three Glenlake Building.
- (l) Represents interest expense related to the \$25.0 million mortgage note obtained in conjunction with the acquisition of the Three Glenlake Building. The mortgage note bears interest at 5.95% and matures on July 31, 2013.

The accompanying notes are an integral part of this statement